A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro
Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/28/4/1693 |
| _version_ | 1797619037426941952 |
|---|---|
| author | Seongtae Jeong Bok-Sim Lee Seung Eun Jung Yoojin Yoon Byeong-Wook Song Il-Kwon Kim Jung-Won Choi Sang Woo Kim Seahyoung Lee Soyeon Lim |
| author_facet | Seongtae Jeong Bok-Sim Lee Seung Eun Jung Yoojin Yoon Byeong-Wook Song Il-Kwon Kim Jung-Won Choi Sang Woo Kim Seahyoung Lee Soyeon Lim |
| author_sort | Seongtae Jeong |
| collection | DOAJ |
| description | Vascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type 1 receptor blockers (ARBs), improved both vascular calcification and hip fracture in elderly. However, a sex-dependent discrepancy in the responsiveness to ARB treatment in hip fracture was observed, possibly due to the estrogen deficiency in older women, suggesting that blocking the angiotensin signaling pathway may not be effective to suppress bone resorption, especially if an individual has underlying osteoclast activating conditions such as estrogen deficiency. Therefore, it has its own significance to find alternative modality for inhibiting both vascular calcification and osteoporosis by directly targeting osteoclast activation to circumvent the shortcoming of ARBs in preventing bone resorption in estrogen deficient individuals. In the present study, a natural compound library was screened to find chemical agents that are effective in preventing both calcium deposition in vascular smooth muscle cells (vSMCs) and activation of osteoclast using experimental methods such as Alizarin red staining and Tartrate-resistant acid phosphatase staining. According to our data, citreoviridin (CIT) has both an anti-VC effect and anti-osteoclastic effect in vSMCs and in Raw 264.7 cells, respectively, suggesting its potential as an effective therapeutic agent for both VC and osteoporosis. |
| first_indexed | 2024-03-11T08:22:29Z |
| format | Article |
| id | doaj.art-b023892c13a64a57977065dba7aa5086 |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-11T08:22:29Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-b023892c13a64a57977065dba7aa50862023-11-16T22:22:00ZengMDPI AGMolecules1420-30492023-02-01284169310.3390/molecules28041693A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In VitroSeongtae Jeong0Bok-Sim Lee1Seung Eun Jung2Yoojin Yoon3Byeong-Wook Song4Il-Kwon Kim5Jung-Won Choi6Sang Woo Kim7Seahyoung Lee8Soyeon Lim9The Interdisciplinary Graduate Program in Integrative Biotechnology & Translational Medicine (IBTM), Graduate School, Yonsei University, Seoul 03722, Republic of KoreaInstitute for Bio-Medical Convergence, Catholic Kwandong University International St. Mary’s Hospital, Incheon 22711, Republic of KoreaInstitute for Bio-Medical Convergence, Catholic Kwandong University International St. Mary’s Hospital, Incheon 22711, Republic of KoreaDepartment for Medical Science, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaInstitute for Bio-Medical Convergence, College of Medicine, Catholic Kwandong University, Gangneung-si 25601, Republic of KoreaVascular calcification (VC) and osteoporosis are age-related diseases and significant risk factors for the mortality of elderly. VC and osteoporosis may share common risk factors such as renin-angiotensin system (RAS)-related hypertension. In fact, inhibitors of RAS pathway, such as angiotensin type 1 receptor blockers (ARBs), improved both vascular calcification and hip fracture in elderly. However, a sex-dependent discrepancy in the responsiveness to ARB treatment in hip fracture was observed, possibly due to the estrogen deficiency in older women, suggesting that blocking the angiotensin signaling pathway may not be effective to suppress bone resorption, especially if an individual has underlying osteoclast activating conditions such as estrogen deficiency. Therefore, it has its own significance to find alternative modality for inhibiting both vascular calcification and osteoporosis by directly targeting osteoclast activation to circumvent the shortcoming of ARBs in preventing bone resorption in estrogen deficient individuals. In the present study, a natural compound library was screened to find chemical agents that are effective in preventing both calcium deposition in vascular smooth muscle cells (vSMCs) and activation of osteoclast using experimental methods such as Alizarin red staining and Tartrate-resistant acid phosphatase staining. According to our data, citreoviridin (CIT) has both an anti-VC effect and anti-osteoclastic effect in vSMCs and in Raw 264.7 cells, respectively, suggesting its potential as an effective therapeutic agent for both VC and osteoporosis.https://www.mdpi.com/1420-3049/28/4/1693vascular calcificationosteoporosiscitreoviridin |
| spellingShingle | Seongtae Jeong Bok-Sim Lee Seung Eun Jung Yoojin Yoon Byeong-Wook Song Il-Kwon Kim Jung-Won Choi Sang Woo Kim Seahyoung Lee Soyeon Lim A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro Molecules vascular calcification osteoporosis citreoviridin |
| title | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
| title_full | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
| title_fullStr | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
| title_full_unstemmed | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
| title_short | A Low Concentration of Citreoviridin Prevents Both Intracellular Calcium Deposition in Vascular Smooth Muscle Cell and Osteoclast Activation In Vitro |
| title_sort | low concentration of citreoviridin prevents both intracellular calcium deposition in vascular smooth muscle cell and osteoclast activation in vitro |
| topic | vascular calcification osteoporosis citreoviridin |
| url | https://www.mdpi.com/1420-3049/28/4/1693 |
| work_keys_str_mv | AT seongtaejeong alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT boksimlee alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT seungeunjung alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT yoojinyoon alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT byeongwooksong alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT ilkwonkim alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT jungwonchoi alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT sangwookim alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT seahyounglee alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT soyeonlim alowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT seongtaejeong lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT boksimlee lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT seungeunjung lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT yoojinyoon lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT byeongwooksong lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT ilkwonkim lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT jungwonchoi lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT sangwookim lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT seahyounglee lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro AT soyeonlim lowconcentrationofcitreoviridinpreventsbothintracellularcalciumdepositioninvascularsmoothmusclecellandosteoclastactivationinvitro |